NMRA

TentativeAI Memo

Neumora Therapeutics

As of 2026-10-07/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-07 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

low

Horizon

—

Key catalyst

NMRA-898 Phase 1 data • 2026-12-31

Base target: $0 / p=45% prob

Biggest risk

Navacaprant failed the primary and key secondary endpoints in KOASTAL-2 and -3, prompting discontinuation and an approximately 35% workforce reduction; the remaining programs are earlier-stage and carry substantial translation risk (June 15 SEC 8-K). A delayed or weak readout could make financing risk more immediate.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Timely, informative NMRA-898 and NMRA-511 data plus NMRA-215's first-in-human transition could restore confidence in the post-navacaprant pipeline. Neumora reported $116.8 million of cash at June 30 and expected funding into the third quarter of 2027 [#SEC-8K-2026-08-14].

Research note

Recommendation

—

Confidence

low

As of

2026-10-07

Base target

p=45%

Bull target

p=20%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

NMRA-215 IND and first-in-human transition
Timely, informative NMRA-898 and NMRA-511 data plus NMRA-215's first-in-human transition could restore confidence in the post-navacaprant pipeline.
Neumora reported $116.8 million of cash at June 30 and expected funding into the third quarter of 2027 [#SEC-8K-2026-08-14].

BearKey bullets

NMRA-898 and NMRA-511 data may be inconclusive or fail to translate into patient efficacy; NMRA-215 remains preclinical pending its planned IND [#SEC-8K-2026-08-14].
Second-quarter R&D expense was $29.3 million and net loss was $43.1 million.
The stated cash runway into the third quarter of 2027 depends on the operating plan and does not eliminate future financing or dilution risk [#SEC-8K-2026-08-14].

WatchKey bullets

NMRA-898 Phase 1 data

Summary

High-level snapshot

Recommendation

Model confidence

low

Timeframe

Asset

Equity

Trigger

Base case: $0 (p=45%)

Target spread vs base: +100% / -55%

Scenario probabilities

Bull Target: $1 (p=20%)Base Target: $0 (p=45%)Bear Target: $0 (p=35%)

Commentary

The October 6 $0.471 anchor is about 30% below the prior baseline's September 25 $0.6776 anchor; the packet does not establish why it fell. Available news centers on the June clinical setback, while the August company update provides specific year-end milestones. Reliable recent analyst revisions, options, short-interest, employee and sufficient social data were not supplied; zero-valued sentiment fields mean unavailable, not neutral. The revised peers offer indication or CNS context but remain unsuitable for standard-conviction valuation. Low coverage limits conviction.

As of 2026-10-07 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

NMRA-215 IND and first-in-human transition

Scenarios

Bull Target (Scenario probability)

$1 / p=20% prob

Base Target (Scenario probability)

$0 / p=45% prob

Bear Target (Scenario probability)

$0 / p=35% prob

Analysis 2026-10-07 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
NMRA-898 Phase 1 data
Neumora expects second-half 2026 multiple-ascending-dose data from healthy volunteers and patients with stable schizophrenia. Safety and pharmacology could change confidence in the remaining pipeline, but this is not a pivotal efficacy readout [#8-K-2026-08-14] [#SEC-8K-2026-08-14].
Prob 60.00% • Move 40.00% • Priced-in 20.00%
EVENT2026-12-31
NMRA-511 dose-expansion data and Phase 2 start
The company plans fourth-quarter 2026 higher-dose data from healthy elderly participants and aims to initiate a Phase 2 Alzheimer's disease agitation study by year-end. Translation into patient benefit remains unproven [#SEC-8K-2026-08-14] [#PR-EARNINGS-2026-08-14].
Prob 55.00% • Move 35.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

NMRA-215 IND and first-in-human transition
2026-12-31
Neumora expects a fourth-quarter 2026 IND submission and Phase 1 initiation by year-end for NMRA-215. A timely transition would broaden the clinical pipeline, not establish efficacy [#SEC-8K-2026-08-14] [#PR-EARNINGS-2026-08-14].
Prob 60% • Move 20% • Priced-in 15%

Risks

NMRA-898 and NMRA-511 data may be inconclusive or fail to translate into patient efficacy; NMRA-215 remains preclinical pending its planned IND [#SEC-8K-2026-08-14].
Second-quarter R&D expense was $29.3 million and net loss was $43.1 million. The stated cash runway into the third quarter of 2027 depends on the operating plan and does not eliminate future financing or dilution risk [#SEC-8K-2026-08-14].
The June Phase 3 navacaprant failures removed the former lead depression program; Neumora discontinued development and announced a workforce reduction (June 15 SEC 8-K).

Peers

Symbol	Summary
AXSM	Axsome's AXS-05 is being developed for Alzheimer's disease agitation, directly overlapping NMRA-511's intended indication. Axsome has a different mechanism, later development and commercial operations, so it is an indication comparator, not a valuation multiple for Neumora (Axsome pipeline).
CGTX	Cognition Therapeutics, a packet-listed similar-cap biotech, develops zervimesine for neurodegenerative conditions including Alzheimer's disease and dementia with Lewy bodies. Its Phase 2 program offers a closer CNS clinical-risk comparison than broad sector peers, but neither indication nor mechanism matches NMRA-511 and it is not a direct valuation peer (Cognition company update).

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-07

Loading AI feed…

Symbol

Summary

AXSM

Axsome's AXS-05 is being developed for Alzheimer's disease agitation, directly overlapping NMRA-511's intended indication. Axsome has a different mechanism, later development and commercial operations, so it is an indication comparator, not a valuation multiple for Neumora (Axsome pipeline).

CGTX

Cognition Therapeutics, a packet-listed similar-cap biotech, develops zervimesine for neurodegenerative conditions including Alzheimer's disease and dementia with Lewy bodies. Its Phase 2 program offers a closer CNS clinical-risk comparison than broad sector peers, but neither indication nor mechanism matches NMRA-511 and it is not a direct valuation peer (Cognition company update).